Investment Thesis
Wave Life Sciences faces severe operational deterioration with revenue collapsing 60.5% YoY and generating negative free cash flow of -$60M annually. While the balance sheet provides near-term runway through substantial cash reserves, the unprofitable operations, declining sales, and negative margins indicate fundamental business failure, suggesting the core pipeline or commercial strategy is failing.
Strengths
- Strong cash position of $544.6M provides operational runway for approximately 9 years at current burn rate
- Zero debt burden with Debt/Equity ratio of 0.00x and low liabilities of $71.8M
- Excellent liquidity ratios (Current Ratio 11.26x) enabling continued funding without asset sales or distress financing
Risks
- Revenue collapsed 60.5% year-over-year indicating severe commercial or clinical setbacks in core products
- Negative free cash flow of -$60.0M annually with FCF margin of -156.9% showing operations are cash destructive
- Deeply unprofitable with operating margin of -81.8% and net margin of -68.2%, generating $26.1M net losses
- Diluted EPS deteriorated 72.9% YoY to -$0.13, reflecting worsening per-share economics
- Cash burn will deplete reserves within 9 years even if stabilized at current levels without positive cash flow inflection
Key Metrics to Watch
- Quarterly revenue trend stabilization or further deterioration
- Operating cash flow path to positive; current -$59.6M burn is unsustainable long-term
- Clinical trial pipeline progress and regulatory approval timeline for next-stage products
- Cash runway duration and monthly cash burn rate acceleration/deceleration
- Gross margin recovery upon successful product commercialization to offset operating losses
Financial Metrics
Revenue
38.2M
Net Income
-26.1M
EPS (Diluted)
$-0.13
Free Cash Flow
-60.0M
Total Assets
583.5M
Cash
544.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-81.8%
Net Margin
-68.2%
ROE
-5.1%
ROA
-4.5%
FCF Margin
-156.9%
Balance Sheet & Liquidity
Current Ratio
11.26x
Quick Ratio
11.26x
Debt/Equity
0.00x
Debt/Assets
12.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T14:10:41.805335 |
Data as of: 2026-03-31 |
Powered by Claude AI